Proliferative Vitreoretinopathy Market
Proliferative Vitreoretinopathy Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2018 to 2027
Analysis of Proliferative Vitreoretinopathy market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Introduction
Proliferative vitreoretinopathy (PVR) remains the most commonly observed failure in the surgery of rhegmatogenous retinal detachment (RRD), albeit substantial efforts have been taken to better understand and manage the condition in the past.
Basic research indicates that proliferative vitreoretinopathy illustrates scarring - end-stage of wound healing process, which occurs post-retinal detachment surgery.
Current medical treatment for PVR has been directed toward the prevention of inflammation - first stage of wound-healing process, and inhibition of cell proliferation - second stage.
Surgery for proliferative vitreoretinopathy, at present, demonstrates high anatomical success rate, despite disappointing visual results.
Utilization of adjunctive treatments for preventing cellular proliferation has been deemed effective in the treatment & prevention of PVR, or post-surgery recurrences.
Proliferation control and strategies directed toward the improvement of visual outcome are imperative focus areas for future studies in PVR.
In addition, researches on the peri-retinal and intra-retinal pathology of proliferative vitreoretinopathy have illustrated characteristic alterations, which will significantly influence surgical management and visual outcome.
A recent Fact.MR report foresees the proliferative vitreoretinopathy market to record a moderate rise over the period of forecast (2018 to 2027).
Revenues from treatment and management of proliferative vitreoretinopathy worldwide will reach nearly US$ 660 Mn by 2027-end.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Proliferative Vitreoretinopathy Market: Potential of Systemic Anti-TNF? Treatment in Reduction of PVR to Influence Future Developments
Lack of effective prophylaxis or treatment has made proliferative vitreoretinopathy one of the most devastating complications witnessed in RRD.
TNFα has been implied in PVR development, which in turn necessitates blockade of this factor for reducing or preventing onset of proliferative vitreoretinopathy.
However, systemic treatment of PVR using anti-TNFα entails several side-effects and risks, and employment of such drugs for PVR treatment is not yet justified.
Researchers have sought indirect approaches for determination of effectiveness of anti-TNFα in protection against PVR development post-RRD surgery.
Despite sound principles on which the approaches are based, low prevalence of patients affected with RRD, chronic inflammatory diseases, and PVR has prevented researchers from drawing conclusions with regard to potential effectiveness of the anti-TNFα therapy as prophylactic treatment for preventing or reducing PVR incidences following RRD.
However, these approaches hold promise in promoting future in-vivo studies, and randomizing clinical trials in humans with the help of more preclinical research.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Proliferative Vitreoretinopathy Market: New PVR Development Suppression & Prevention Methods to Underpin Growth
Proliferative vitreoretinopathy, an inflammatory fibrotic disease, stems from inflammatory milieu post-RRD, which in turn prevents retinal healing.
Several studies aimed at suppressing or preventing the development of PVR are being conducted worldwide, with some of the recent ones elucidating effect of “substance P (SP),” and targeted use of non-steroidal anti-inflammatory drugs such as “lornoxicam.”
Research carried out on lornoxicam has not only demonstrated successful improvement in the condition of retina and choroid, but also reduced frequency of membrane formation significantly.
Studies conducted on substance P have revealed that SP has the capability of inhibiting apoptosis, and epithelial-mesenchymal transition (EMT) induced by TNFα caused, thereby suppressing or preventing development of proliferative retinopathy.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis and Forecast
- 6.1. Treatment Type
- 6.2. Drug Class
- 6.3. End-User
- 6.4. Distribution Channel
- 7. Global Market Analysis and Forecast, By Treatment Type
- 7.1. Pharmacological Treatments
- 7.2. Surgical Treatments
- 7.3. Combination Treatments
- 8. Global Market Analysis and Forecast, By Drug Class
- 8.1. Anti-Inflammatory Agents
- 8.2. Immunosuppressants
- 8.3. Anti-VEGF Drugs
- 8.4. Others
- 9. Global Market Analysis and Forecast, By End-User
- 9.1. Hospitals
- 9.2. Specialty Eye Clinics
- 9.3. Ambulatory Surgical Centers (ASCs)
- 9.4. Research and Academic Institutes
- 10. Global Market Analysis and Forecast, By Distribution Channel
- 10.1. Hospital Pharmacies
- 10.2. Retail Pharmacies
- 10.3. Online Pharmacies
- 10.4. Specialty Pharmacies
- 11. Global Market Analysis and Forecast, By Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Western Europe
- 11.4. Eastern Europe
- 11.5. Asia Pacific
- 11.6. East Asia
- 11.7. MEA
- 12. North America Sales Analysis and Forecast, by Key Segments and Countries
- 13. Latin America Sales Analysis and Forecast, by Key Segments and Countries
- 14. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
- 15. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries
- 16. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries
- 17. East Asia Sales Analysis and Forecast, by Key Segments and Countries
- 18. MEA Sales Analysis and Forecast, by Key Segments and Countries
- 19. Sales Forecast by Treatment Type, Drug Class, End-User, and Distribution Channel for 30 Countries
- 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 21. Company Profile
- 21.1. Novartis AG
- 21.2. Regeneron Pharmaceuticals, Inc.
- 21.3. Genentech, Inc.
- 21.4. Pfizer, Inc.
- 21.5. Allergan Plc
- 21.6. Aldeyra Therapeutics, Inc.
- 21.7. Alimera Sciences
- 22. Context Menu
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 1 Global Market Value (US$ Mn), 2013 to 2018
TABLE 2 Global Market Value (US$ Mn), 2019 to 2027
TABLE 3 Global Market Value (US$ Mn) and Y-o-Y, 2018 to 2027
TABLE 4 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 5 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 6 Global Anti-VEGF Agents Segment Market Share, By Region 2013 to 2018
TABLE 7 Global Anti-VEGF Agents Segment Market Share, By Region 2019 to 2027
TABLE 8 Global Anti-VEGF Agents Segment Y-o-Y, By Region 2018 to 2027
TABLE 9 Global Corticosteroids Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 10 Global Corticosteroids Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 11 Global Corticosteroids Segment Market Share, By Region 2013 to 2018
TABLE 12 Global Corticosteroids Segment Market Share, By Region 2019 to 2027
TABLE 13 Global Corticosteroids Segment Y-o-Y, By Region 2018 to 2027
TABLE 14 Global Anti-TGF Beta Antibody Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 15 Global Anti-TGF Beta Antibody Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 16 Global Anti-TGF Beta Antibody Segment Market Share, By Region 2013 to 2018
TABLE 17 Global Anti-TGF Beta Antibody Segment Market Share, By Region 2019 to 2027
TABLE 18 Global Anti-TGF Beta Antibody Segment Y-o-Y, By Region 2018 to 2027
TABLE 19 Global Injectables Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 20 Global Injectables Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 21 Global Injectables Segment Market Share, By Region 2013 to 2018
TABLE 22 Global Injectables Segment Market Share, By Region 2019 to 2027
TABLE 23 Global Injectables Segment Y-o-Y, By Region 2018 to 2027
TABLE 24 Global Oral Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 25 Global Oral Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 26 Global Oral Segment Market Share, By Region 2013 to 2018
TABLE 27 Global Oral Segment Market Share, By Region 2019 to 2027
TABLE 28 Global Oral Segment Y-o-Y, By Region 2018 to 2027
TABLE 29 Global Others Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 30 Global Others Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 31 Global Others Segment Market Share, By Region 2013 to 2018
TABLE 32 Global Others Segment Market Share, By Region 2019 to 2027
TABLE 33 Global Others Segment Y-o-Y, By Region 2018 to 2027
TABLE 34 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 35 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 36 Global Hospital Pharmacies Segment Market Share, By Region 2013 to 2018
TABLE 37 Global Hospital Pharmacies Segment Market Share, By Region 2019 to 2027
TABLE 38 Global Hospital Pharmacies Segment Y-o-Y, By Region 2018 to 2027
TABLE 39 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 40 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 41 Global Retail Pharmacies Segment Market Share, By Region 2013 to 2018
TABLE 42 Global Retail Pharmacies Segment Market Share, By Region 2019 to 2027
TABLE 43 Global Retail Pharmacies Segment Y-o-Y, By Region 2018 to 2027
TABLE 44 Global Online Pharmacies Segment Value (US$ Mn), By Region 2013 to 2018
TABLE 45 Global Online Pharmacies Segment Value (US$ Mn), By Region 2019 to 2027
TABLE 46 Global Online Pharmacies Segment Market Share, By Region 2013 to 2018
TABLE 47 Global Online Pharmacies Segment Market Share, By Region 2019 to 2027
TABLE 48 Global Online Pharmacies Segment Y-o-Y, By Region 2018 to 2027
TABLE 49 North America Market Value (US$ Mn), By Country 2013 to 2018
TABLE 50 North America Market Value (US$ Mn), By Country 2019 to 2027
TABLE 51 North America Market Value (US$ Mn), By Drug Class 2013 to 2018
TABLE 52 North America Market Value (US$ Mn), By Drug Class 2019 to 2027
TABLE 53 North America Market Value (US$ Mn), By Mode of Administration 2013 to 2018
TABLE 54 North America Market Value (US$ Mn), By Mode of Administration 2019 to 2027
TABLE 55 North America Market Value (US$ Mn), By Distribution Channel 2013 to 2018
TABLE 56 North America Market Value (US$ Mn), By Distribution Channel 2019 to 2027
TABLE 57 Latin America Market Value (US$ Mn), By Country 2013 to 2018
TABLE 58 Latin America Market Value (US$ Mn), By Country 2019 to 2027
TABLE 59 Latin America Market Value (US$ Mn), By Drug Class 2013 to 2018
TABLE 60 Latin America Market Value (US$ Mn), By Drug Class 2019 to 2027
TABLE 61 Latin America Market Value (US$ Mn), By Mode of Administration 2013 to 2018
TABLE 62 Latin America Market Value (US$ Mn), By Mode of Administration 2019 to 2027
TABLE 63 Latin America Market Value (US$ Mn), By Distribution Channel 2013 to 2018
TABLE 64 Latin America Market Value (US$ Mn), By Distribution Channel 2019 to 2027
TABLE 65 Europe Market Value (US$ Mn), By Country 2013 to 2018
TABLE 66 Europe Market Value (US$ Mn), By Country 2019 to 2027
TABLE 67 Europe Market Value (US$ Mn), By Drug Class 2013 to 2018
TABLE 68 Europe Market Value (US$ Mn), By Drug Class 2019 to 2027
TABLE 69 Europe Market Value (US$ Mn), By Mode of Administration 2013 to 2018
TABLE 70 Europe Market Value (US$ Mn), By Mode of Administration 2019 to 2027
TABLE 71 Europe Market Value (US$ Mn), By Distribution Channel 2013 to 2018
TABLE 72 Europe Market Value (US$ Mn), By Distribution Channel 2019 to 2027
TABLE 73 Japan Market Value (US$ Mn), By Country 2013 to 2018
TABLE 74 Japan Market Value (US$ Mn), By Country 2019 to 2027
TABLE 75 Japan Market Value (US$ Mn), By Drug Class 2013 to 2018
TABLE 76 Japan Market Value (US$ Mn), By Drug Class 2019 to 2027
TABLE 77 Japan Market Value (US$ Mn), By Mode of Administration 2013 to 2018
TABLE 78 Japan Market Value (US$ Mn), By Mode of Administration 2019 to 2027
TABLE 79 Japan Market Value (US$ Mn), By Distribution Channel 2013 to 2018
TABLE 80 Japan Market Value (US$ Mn), By Distribution Channel 2019 to 2027
TABLE 81 APEJ Market Value (US$ Mn), By Country 2013 to 2018
TABLE 82 APEJ Market Value (US$ Mn), By Country 2019 to 2027
TABLE 83 APEJ Market Value (US$ Mn), By Drug Class 2013 to 2018
TABLE 84 APEJ Market Value (US$ Mn), By Drug Class 2019 to 2027
TABLE 85 APEJ Market Value (US$ Mn), By Mode of Administration 2013 to 2018
TABLE 86 APEJ Market Value (US$ Mn), By Mode of Administration 2019 to 2027
TABLE 87 APEJ Market Value (US$ Mn), By Distribution Channel 2013 to 2018
TABLE 88 APEJ Market Value (US$ Mn), By Distribution Channel 2019 to 2027
TABLE 89 MEA Market Value (US$ Mn), By Country 2013 to 2018
TABLE 90 MEA Market Value (US$ Mn), By Country 2019 to 2027
TABLE 91 MEA Market Value (US$ Mn), By Drug Class 2013 to 2018
TABLE 92 MEA Market Value (US$ Mn), By Drug Class 2019 to 2027
TABLE 93 MEA Market Value (US$ Mn), By Mode of Administration 2013 to 2018
TABLE 94 MEA Market Value (US$ Mn), By Mode of Administration 2019 to 2027
TABLE 95 MEA Market Value (US$ Mn), By Distribution Channel 2013 to 2018
TABLE 96 MEA Market Value (US$ Mn), By Distribution Channel 2019 to 2027
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 1 Global Market Value (US$ Mn), 2013 to 2018
FIG. 2 Global Market Value (US$ Mn) Forecast, 2019 to 2027
FIG. 3 Global Market Value (US$ Mn) and Y-o-Y, 2018 to 2027
FIG. 4 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 5 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 6 Global Anti-VEGF Agents Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 7 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 8 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 9 Global Corticosteroids Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 10 Global Anti-TGF Beta Antibody Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 11 Global Anti-TGF Beta Antibody Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 12 Global Anti-TGF Beta Antibody Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 13 Global Injectables Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 14 Global Injectables Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 15 Global Injectables Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 16 Global Oral Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 17 Global Oral Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 18 Global Oral Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 19 Global Others Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 20 Global Others Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 21 Global Others Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 22 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 23 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 24 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 25 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 26 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 27 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 28 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 29 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 30 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2018 to 2027
FIG. 31 North America Market Value (US$ Mn), By Country 2013 to 2018
FIG. 32 North America Market Value (US$ Mn), By Country 2019 to 2027
FIG. 33 North America Market Value (US$ Mn), By Drug Class 2013 to 2018
FIG. 34 North America Market Value (US$ Mn), By Drug Class 2019 to 2027
FIG. 35 North America Market Value (US$ Mn), By Mode of Administration 2013 to 2018
FIG. 36 North America Market Value (US$ Mn), By Mode of Administration 2019 to 2027
FIG. 37 North America Market Value (US$ Mn), By Distribution Channel 2013 to 2018
FIG. 38 North America Market Value (US$ Mn), By Distribution Channel 2019 to 2027
FIG. 39 Latin America Market Value (US$ Mn), By Country 2013 to 2018
FIG. 40 Latin America Market Value (US$ Mn), By Country 2019 to 2027
FIG. 41 Latin America Market Value (US$ Mn), By Drug Class 2013 to 2018
FIG. 42 Latin America Market Value (US$ Mn), By Drug Class 2019 to 2027
FIG. 43 Latin America Market Value (US$ Mn), By Mode of Administration 2013 to 2018
FIG. 44 Latin America Market Value (US$ Mn), By Mode of Administration 2019 to 2027
FIG. 45 Latin America Market Value (US$ Mn), By Distribution Channel 2013 to 2018
FIG. 46 Latin America Market Value (US$ Mn), By Distribution Channel 2019 to 2027
FIG. 47 Europe Market Value (US$ Mn), By Country 2013 to 2018
FIG. 48 Europe Market Value (US$ Mn), By Country 2019 to 2027
FIG. 49 Europe Market Value (US$ Mn), By Drug Class 2013 to 2018
FIG. 50 Europe Market Value (US$ Mn), By Drug Class 2019 to 2027
FIG. 51 Europe Market Value (US$ Mn), By Mode of Administration 2013 to 2018
FIG. 52 Europe Market Value (US$ Mn), By Mode of Administration 2019 to 2027
FIG. 53 Europe Market Value (US$ Mn), By Distribution Channel 2013 to 2018
FIG. 54 Europe Market Value (US$ Mn), By Distribution Channel 2019 to 2027
FIG. 55 Japan Market Value (US$ Mn), By Country 2013 to 2018
FIG. 56 Japan Market Value (US$ Mn), By Country 2019 to 2027
FIG. 57 Japan Market Value (US$ Mn), By Drug Class 2013 to 2018
FIG. 58 Japan Market Value (US$ Mn), By Drug Class 2019 to 2027
FIG. 59 Japan Market Value (US$ Mn), By Mode of Administration 2013 to 2018
FIG. 60 Japan Market Value (US$ Mn), By Mode of Administration 2019 to 2027
FIG. 61 Japan Market Value (US$ Mn), By Distribution Channel 2013 to 2018
FIG. 62 Japan Market Value (US$ Mn), By Distribution Channel 2019 to 2027
FIG. 63 APEJ Market Value (US$ Mn), By Country 2013 to 2018
FIG. 64 APEJ Market Value (US$ Mn), By Country 2019 to 2027
FIG. 65 APEJ Market Value (US$ Mn), By Drug Class 2013 to 2018
FIG. 66 APEJ Market Value (US$ Mn), By Drug Class 2019 to 2027
FIG. 67 APEJ Market Value (US$ Mn), By Mode of Administration 2013 to 2018
FIG. 68 APEJ Market Value (US$ Mn), By Mode of Administration 2019 to 2027
FIG. 69 APEJ Market Value (US$ Mn), By Distribution Channel 2013 to 2018
FIG. 70 APEJ Market Value (US$ Mn), By Distribution Channel 2019 to 2027
FIG. 71 MEA Market Value (US$ Mn), By Country 2013 to 2018
FIG. 72 MEA Market Value (US$ Mn), By Country 2019 to 2027
FIG. 73 MEA Market Value (US$ Mn), By Drug Class 2013 to 2018
FIG. 74 MEA Market Value (US$ Mn), By Drug Class 2019 to 2027
FIG. 75 MEA Market Value (US$ Mn), By Mode of Administration 2013 to 2018
FIG. 76 MEA Market Value (US$ Mn), By Mode of Administration 2019 to 2027
FIG. 77 MEA Market Value (US$ Mn), By Distribution Channel 2013 to 2018
FIG. 78 MEA Market Value (US$ Mn), By Distribution Channel 2019 to 2027
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the growth rate of the global Proliferative Vitreoretinopathy market?
The global market is set to record CAGR of 4% and increase in revenue by end of forecast period.
How much is the global market for Proliferative Vitreoretinopathy worth?
The market is estimated to be worth nearly US$ 660 Million.
Proliferative Vitreoretinopathy Market